NIP
NBIX icon

Nicholas Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

Nicholas Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,931
Closed -$404K – 240
2024
Q2 		$404K Buy
+2,931
New +$402K 0.04% 191
2020
Q2 		– Sell
-27,668
Closed -$2.4M – 192
2020
Q1 		$2.4M Sell
27,668
-1,742
-6% -$170K 0.47% 85
2019
Q4 		$3.16M Sell
29,410
-10,521
-26% -$1.1M 0.33% 101
2019
Q3 		$3.6M Buy
39,931
+5,941
+17% +$555K 0.3% 130
2019
Q2 		$2.87M Buy
33,990
+3,644
+12% +$299K 0.26% 126
2019
Q1 		$2.67M Buy
30,346
+7,107
+31% +$594K 0.24% 144
2018
Q4 		$1.66M Buy
23,239
+1,149
+5% +$110K 0.18% 179
2018
Q3 		$2.72M Sell
22,090
-1,211
-5% -$137K 0.22% 168
2018
Q2 		$2.29M Buy
23,301
+2,313
+11% +$207K 0.16% 178
2018
Q1 		$1.74M Buy
+20,988
New +$1.77M 0.12% 198
2016
Q4 		– Sell
-168,624
Closed -$8.54M – 322
2016
Q3 		$8.54M Buy
168,624
+9,202
+6% +$458K 0.57% 30
2016
Q2 		$7.25M Buy
159,422
+93,687
+143% +$4.31M 0.5% 44
2016
Q1 		$2.6M Sell
65,735
-12,537
-16% -$497K 0.19% 207
2015
Q4 		$4.43M Buy
+78,272
New +$3.98M 0.31% 129

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nicholas Investment Partners's NBIX Position: Q3 2024 in Review

Nicholas Investment Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 2,931 shares — an estimated $404K sold.

Nicholas Investment Partners first reported a position in NBIX in Q4 2015 and held it in 14 quarters. The position peaked at $8.54M in Q3 2016. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Nicholas Investment Partners reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 2,931 Neurocrine Biosciences shares in Q3 2024, an estimated $404K.
  • Nicholas Investment Partners first reported a position in Neurocrine Biosciences in Q4 2015 and held it in 14 quarters.
  • Nicholas Investment Partners's Neurocrine Biosciences position peaked at $8.54M in Q3 2016.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Nicholas Investment Partners's 13F filing for Q3 2024, filed 12 Nov 2024.